August 6, 2025

Hims & Hers Health (NYSE: HIMS) is a rapidly growing telehealth company that has been making waves in the personalized care and weight-loss market. However, the company faced significant turbulence following the release of its second-quarter earnings for 2025, resulting in a stock drop of over 11%. While revenue soared by 73% compared to the previous year, the company ultimately fell short of Wall Street's revenue expectations. With Q2 revenues at $544.8 million, analyst estimates were around $552 million, leading to intense scrutiny of the company’s future, particularly regarding its GLP-1 obesity drug business. In the wake of the earnings report, Hims & Hers' stock positioned itself at $63.35. This represented a recovery from an intraday low of $54.82, but overall volatility persisted as the stock traded within a day range of $54.82 to $65.54, starting the day at $64.00 and peaking at $65.54. Investors reacted sharply as the company's revenue miss stood out, despite the fact that adjusted earnings per share of $0.19 exceeded the expected $0.15. The decline in revenue from Q1’s $586 million marked a worrying trend—the first quarter-over-quarter drop since Hims went public. Much of Hims’ revenue stems from its GLP-1-based treatments for obesity and diabetes, areas enjoying a surge in demand but now facing increased scrutiny. Regulatory pressures and legal troubles loom large, particularly a recent supply relationship termination with Novo Nordisk, which manufactures Wegovy. Hims' future reliance on compounded semaglutide, an important element of its weight-loss solutions, now stands on shaky ground, compounded by ongoing lawsuits concerning its marketing practices and the issuance of stricter FDA regulations. Despite these challenges, Hims & Hers maintained an optimistic outlook for its full-year guidance, reaffirming revenue projections between $2.3 billion and $2.4 billion, alongside adjusted EBITDA expectations of $295 million to $335 million. This confidence is partly attributed to the acquisition of European telehealth platform Zava, anticipated to add approximately $50 million to revenues this year. Subscriber growth continues to be a bright spot amid the uncertainty, with Hims reporting over 2.4 million active subscribers, 70% of whom are involved in personalized treatment plans that range across various health categories, including weight loss, hair care, and sexual wellness. CEO Andrew Dudum has emphasized a strategic pivot towards fostering long-term digital healthcare solutions that aim to enhance customer loyalty and lifetime value across multiple product categories. Looking ahead, investors are advised to keep a close eye on several key factors: the future of compounded GLP-1 drugs amid regulatory challenges, profitability trends in a competitive market, subscriber growth and retention in non-weight loss areas, and the integration prospects for the Zava acquisition. Hims & Hers has made notable strides to emerge as a prominent player in the wellness sector through its innovative approach to weight-loss solutions. However, the recent drop in stock price signals a tangible shift in investor sentiment as concerns regarding its primary obesity business surface against a backdrop of regulatory obstacles and operational uncertainties. While Hims retains significant year-over-year growth and steadfast guidance for 2025, it must navigate through escalating competition, tighter FDA rules, and legal battles to solidify its position beyond a singular product wave, aiming instead for a more robust, trusted digital care ecosystem.

Read More at Economictimes →

Tags: Hims & hers, Telehealth, Stock market, Weight loss drugs, Glp-1 treatments,